Fn14 polyclonal, anti-human

Protein Family: Enzymes

Pathway and Disease: Signaling Molecules and Interaction

Description:
TWEAK is a TNF family member produced by IFN-gamma-stimulated monocytes and induces multiple cell death pathways including caspase-dependent apoptosis and cathepsin B-dependent necrosis. These pathways are mediated by the binding of TWEAK by fibroblast growth factor 14 (Fn14), a member of the TNF receptor superfamily. Yeast two-hybrid experiments have shown that FN14 will bind to the TNFR-associated factors TRAF1, TRAF2, TRAF3, and TRAF5, suggesting that the signaling pathway induced by TWEAK may be mediated by one or more of these adaptor molecules. Fn14 is induced during liver regeneration and is highly expressed in hepatocellular carcinomas. In addition, TWEAK induces liver progenitor cell proliferation, suggesting Fn14 may play a role in hepatocyte growth control and liver neoplasia.

Alternate Names: Fn14, Fibroblast growth factor-inducible 14, TNFRSF12, TWEAK-R

Application Notes: E: 1:500-1:1,000; WB: 1:100-1:500; IHC: 1:100-1:500

Accession No.: NP_057723

Antigen: KLH-conjugated synthetic peptide encompassing a sequence within human Fn14.

Format: Each vial contains 0.1 ml IgG in PBS pH 7.4 with 0.02% sodium azide. Antibody was purified by immunogen affinity chromatography.

Storage:
Store at -20°C. Minimize freeze-thaw cycles. Product is guaranteed one year from the date of shipment.